Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pediatr., 09 September 2025

Sec. Obstetric and Pediatric Pharmacology

Volume 13 - 2025 | https://doi.org/10.3389/fped.2025.1694368

Correction: Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a tightrope walk

This article is a correction to:

  1. Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a tightrope walk

    1. Read original article
Nadine Muschel,&#x;Nadine Muschel1,†Michaela Hck,&#x;Michaela Höck2,†Elke GriesmaierElke Griesmaier2Samira Abdel AzimSamira Abdel Azim1Elisabeth RalserElisabeth Ralser2Christina SchreinerChristina Schreiner2Elisabeth SchermerElisabeth Schermer3Ursula Kiechl-KohlendorferUrsula Kiechl-Kohlendorfer2Irene Mutz-Dehbalaie,&#x;Irene Mutz-Dehbalaie1,‡Miriam Michel &#x; Miriam Michel3*‡
  • 1Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria
  • 2Department of Paediatrics II (Neonatology), Medical University of Innsbruck, Innsbruck, Austria
  • 3Department of Paediatrics III (Cardiology, Pulmonology, Allergology and Cystic Fibrosis), Medical University of Innsbruck, Innsbruck, Austria

A Correction on

Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a tightrope walk

By Muschel N, Höck M, Griesmaier E, Azim SA, Ralser E, Schreiner C, Schermer E, Kiechl-Kohlendorfer U, Mutz-Dehbalaie I and Michel M (2025). Front. Pediatr. 13:1649341. doi: 10.3389/fped.2025.1649341

The following Acknowledgments statement was erroneously omitted:

“The authors thank the patient and his family for their kind cooperation, and very much regret the child's adverse outcome. The authors thank E. Michel for manuscript proofreading and T. Klenner for creating the graphic and formatting the tables.”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: adverse effects, fetal cardiac tumor, rhabdomyoma, sirolimus, re-entry tachycardia

Citation: Muschel N, Höck M, Griesmaier E, Azim SA, Ralser E, Schreiner C, Schermer E, Kiechl-Kohlendorfer U, Mutz-Dehbalaie I and Michel M (2025) Correction: Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma—a tightrope walk. Front. Pediatr. 13:1694368. doi: 10.3389/fped.2025.1694368

Received: 28 August 2025; Accepted: 29 August 2025;
Published: 9 September 2025.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright: © 2025 Muschel, Höck, Griesmaier, Azim, Ralser, Schreiner, Schermer, Kiechl-Kohlendorfer, Mutz-Dehbalaie and Michel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Miriam Michel, bWlyaWFtLm1pY2hlbEBpLW1lZC5hYy5hdA==

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share senior authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.